DNA Therapeutics is a clinical stage biopharmaceutical company focused on the development of 1^st-in-class target therapeutics based on an original concept: DNA repair signal jamming, in order to sensitize resistant cancer to conventional cancer therapies such as radiotherapy and chemotherapy.

The 1^st DNA repair signal jamming-based molecule, Dbait, is a mimic of DNA double strand break (DSB). Dbait is used to divert and disorganize DSB repair system responsible of recognizing and fixing DSBs in cells. The aim of Dbait is to compromise cancer cells' enhanced capacity to repair the DSBs caused by conventional therapies, thus to sensitize resistant tumros to these treatments. Please watch a 5 minutes cartoon video which shows how Dbait selectively kills cancer cells (Français/English/中文 subtitle).

Preclinical proofs of concept of Dbait have been achieved in various tumor models in association with radiotherapy or chemotherapy. Biomarkers of Dbait have been identified and under development.

DRIIM, the 1^st-in-human trial of DT01 (a cholesterol-Dbait conjugate) combines with radiotherapy in the patients with local metastatic melanoma has been initiated in Q4 2011 in France. The presence of multiple metastatic tumor nodules on the skin allows to treat on a same patient part of the nodules with DT01 and irradiation, and others with only irradiation. This trial design provides the opportunity to evaluate not only the safety and tolerance, but also to provide a solid clinical proof of the concept of DT01 since tumors treated by DT01 and radiotherapy have their controls treated by radiotherapy alone.

DNA Therapeutics believes that Dbait opens the era of supra-molecular therapy (protein complex pathway targeting).

=> For more details, please check our flyer or fact sheet